Author: iBio, Inc.

Posted Date:

April 8, 2026

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio, Inc.

April 8, 2026
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio, Inc.

March 17, 2026
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio, Inc.

March 9, 2026
iBio to Participate in Upcoming Investor Conferences

iBio, Inc.

February 24, 2026
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc.

February 16, 2026